Citius Oncology, Inc. CTOR Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Citius Oncology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about Citius Oncology, Inc.'s investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Citius Oncology, Inc.'s investing cash flow?
- Citius Oncology, Inc. (CTOR) reported investing cash flow of -$600K in Q1 2026.
- How has Citius Oncology, Inc.'s investing cash flow changed year-over-year?
- Citius Oncology, Inc.'s investing cash flow increased by 58.3% year-over-year, from -$1.44M to -$600K.
- What is the long-term trend for Citius Oncology, Inc.'s investing cash flow?
- Over 2 years (2023 to 2025), Citius Oncology, Inc.'s investing cash flow has grown at a -70.8% compound annual growth rate (CAGR), from -$67.32M to -$5.75M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.